Conduit Pharmaceuticals (CDT) announced that it has entered into an agreement with SARBOR to leverage an advanced artificial intelligence and cybernetics platform to evaluate key deliverables across multiple areas of the Company’s operations, including drug repurposing, drug discovery, solid-form identification, and clinical trial monitoring. By entering into this agreement with Sarborg, Conduit will address longstanding challenges in the pharmaceutical sector by seeking to reduce human error in critical decision-making processes including clinical development and asset identification. By integrating Sarborg’s algorithmic AI and cybernetics technology, Conduit aims to enhance efficiency, lower costs, and accelerate timelines by minimizing human intervention, ultimately optimizing the drug development cycle and giving Conduit a significant competitive advantage.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDT:
- Conduit Pharmaceuticals files to sell 75M shares of common stock for holders
- Conduit Pharmaceuticals receives further patent approval for AZD1656
- Conduit Pharmaceuticals Announces Leadership Changes and Bylaws Update
- Conduit Pharmaceuticals announces new addition to autoimmune pipeline
- Conduit Pharmaceuticals Secures Funding and Modifies Debt Agreements